Skip to content
Sign in
StableHealthPolicyScienceReported 2026-11-20 01:04

Hagens Berman investigation launched into Madrigal Pharmaceuticals over whistleblower clinical data integrity claims

Hagens Berman announced an investigation into Madrigal Pharmaceuticals following a whistleblower complaint filed in October 2026 alleging suppressed liver-injury data, efficacy discrepancies, and improper board oversight of Rezdiffra clinical trials. The firm is examining whether executives misrepresented data integrity and regulatory compliance.

Why it matters. Investors who suffered losses in MDGL securities are encouraged to submit information; the investigation could lead to regulatory action or securities litigation affecting the stock and the drug's market position.

01

Who and what it touches

Ribocure Pharmaceutic…agreement withSuzhou Ribo Life Scie…agreement withArrowhead Pharmaceuti…agreement withMadrigal Pharma…

Into Madrigal Pharmaceuticals

From Madrigal Pharmaceuticals

Each line is a relation with evidence behind it, drawn in the direction it points. A line shows that two things are connected, not how far this change reaches.

02

Evidence

  • PPR Newswire news releasesCompany2026-11-20 01:04
    SAN FRANCISCO, Nov. 19, 2026 /PRNewswire/ -- Hagens Berman, a national complex securities litigation law firm, announces an investigation into **Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)**. The inquiry focuses on whether Madrigal and senior management misrepresented or conce…
    View source